Listing 6.06 in 2026: How Social Security Decides Nephrotic Syndrome Disability Claims, Why the 90-Day Lab Rule and Anasarca Both Have to Be Documented, and the Workup Most Files Are Missing

By Anthony Albert, Benefits Research Director · Published June 16, 2026 · 13 min read

Nephrotic syndrome is one of those impairments where the listing reads simple and the cases get denied anyway. Two lab criteria, one clinical criterion. Easy on paper. The problem is that almost no file shows up at SSA with the right labs at the right time intervals and the right clinical documentation. Adjudicators deny on the paperwork gap, not the underlying disease.

If you have nephrotic syndrome and you are filing for SSDI or SSI, here is what Listing 6.06 actually requires, what proteinuria and albumin thresholds matter, and what your nephrology file has to contain before you submit.

What nephrotic syndrome means at SSA

Nephrotic syndrome is a clinical syndrome, not a single disease. It is caused by an abnormality of glomerular filtration that allows large amounts of protein to leak from the blood into the urine. The classic triad is heavy proteinuria, low serum albumin, and edema, plus usually elevated cholesterol.

The underlying causes that bring patients to nephrology with nephrotic syndrome include:

• Minimal change disease
• Focal segmental glomerulosclerosis (FSGS)
• Membranous nephropathy
• Membranoproliferative glomerulonephritis
• Diabetic nephropathy
• Lupus nephritis (especially classes III, IV, V)
• Amyloidosis
• Multiple myeloma
• HIV-associated nephropathy
• Heroin-associated nephropathy

SSA does not require a renal biopsy to establish nephrotic syndrome under 6.06, but a biopsy almost always exists in real cases because nephrologists biopsy adults with nephrotic-range proteinuria to identify the underlying pathology. If your file has a biopsy report, it should be in the SSA package.

Two background facts shape every nephrotic syndrome claim. First, the syndrome is not a single disease but a downstream consequence of glomerular damage. The treatment plan and prognosis depend on the underlying cause, not the syndrome itself. A minimal change disease patient often responds well to steroids and may remit completely within months. A primary FSGS patient often progresses to end-stage renal disease over years despite aggressive immunosuppression. SSA does not draw distinctions between causes at the listing level, but the underlying pathology shapes the file you build and the trajectory you describe.

Second, nephrotic-range proteinuria carries clinical risks beyond kidney function. Loss of immunoglobulins increases infection risk. Loss of antithrombin III and other natural anticoagulants creates a hypercoagulable state with elevated risk of deep vein thrombosis, pulmonary embolism, and renal vein thrombosis. Loss of vitamin D binding protein causes vitamin D deficiency. Loss of transferrin causes iron-deficiency anemia. These complications often drive the functional limitations in nephrotic syndrome cases, even more than the kidney disease itself.

The exact 6.06 language

Section 6.06 of the Blue Book states that nephrotic syndrome is established with both A and B:

A. Laboratory findings as described in 1 or 2, documented on at least two occasions at least 90 days apart during a consecutive 12-month period:

1. Proteinuria of 10.0 g or greater per 24 hours; or
2. Serum albumin of 3.0 g/dL or less, and one of:
   • Proteinuria of 3.5 g or greater per 24 hours; or
   • Urine total-protein-to-creatinine ratio of 3.5 or greater.

B. Anasarca (see 6.00C6) persisting for at least 90 days despite prescribed treatment.

The word "and" between A and B does the heavy lifting. You need both. Lab criteria alone do not satisfy the listing. Anasarca alone does not either. Almost every denial under 6.06 turns on missing one or the other piece.

The 90-day lab rule, explained

The lab rule in 6.06A is a durability test. SSA wants two documented sets of qualifying labs separated by at least 90 days inside a 12-month window. The point is to rule out transient proteinuria. A single bad lab does not satisfy the rule, even if the number is extreme.

The two paths in 6.06A are:

Path 1: heavy proteinuria alone

Proteinuria of 10.0 g or greater per 24 hours, on two occasions at least 90 days apart. This is a high threshold. Most nephrotic syndrome falls in the 3.5 to 8 g per 24-hour range. Patients who hit 10 g per 24 hours usually have minimal change disease, FSGS, or membranous nephropathy with severe glomerular damage.

Path 2: hypoalbuminemia plus proteinuria or ratio

Serum albumin of 3.0 g/dL or less, and one of:

• Proteinuria of 3.5 g or greater per 24 hours, or
• Urine total-protein-to-creatinine ratio of 3.5 or greater.

This is the more common path. The classic nephrotic patient has albumin in the 2.0 to 2.8 g/dL range with proteinuria of 4 to 8 g per 24 hours. The protein-to-creatinine ratio is a spot urine test that approximates the 24-hour collection and is the most common way nephrologists track proteinuria today, because 24-hour collections are inconvenient and prone to collection error.

SSA accepts the spot urine protein-to-creatinine ratio as a substitute for the 24-hour collection. That is meaningful because many nephrology practices have moved entirely to spot ratios. If your nephrologist orders monthly spot urines instead of quarterly 24-hour collections, your file still satisfies 6.06A as long as two ratios at or above 3.5 are documented 90 days apart.

The anasarca requirement

Anasarca is generalized edema involving multiple body regions. Section 6.00C6 of the Blue Book defines it as severe generalized edema. It is more than ankle swelling. It is generalized fluid retention that involves the lower extremities, abdomen (ascites), pleural space (pleural effusions), face, and scrotum or labia.

The 90-day duration requirement means the anasarca has to persist for at least three months despite prescribed treatment. Prescribed treatment in nephrotic syndrome usually means:

• Loop diuretics (furosemide, torsemide, bumetanide)
• Thiazide or thiazide-like diuretics (metolazone) added for refractory cases
• Potassium-sparing diuretics (spironolactone, eplerenone)
• ACE inhibitors or ARBs for proteinuria reduction
• Salt and fluid restriction
• Treatment of the underlying pathology (steroids, immunosuppressants)

The file has to show the medications, the treatment plan, and the documented persistence of anasarca despite that treatment. A nephrologist's note that says "patient remains volume overloaded with 4+ lower extremity edema, ascites on bedside ultrasound, and bilateral pleural effusions on chest X-ray despite furosemide 80 mg twice daily and metolazone 5 mg daily" satisfies the rule.

Why most files fail the listing

Real-world 6.06 denials cluster around four documentation gaps.

1. Only one set of qualifying labs. The treating nephrologist may have documented severe proteinuria in March and then patient stopped going to appointments. There is no second set of labs at the 90-day mark.
2. Labs are not separated by 90 days. Two sets exist but they are 60 days apart. The listing fails because the durability test is not met.
3. Anasarca is not documented as anasarca. The chart says "trace ankle edema" or "1+ pedal edema" rather than the generalized severe edema 6.06B requires. The reviewer reads the notes and concludes the edema is not anasarca.
4. Treatment regimen is not documented. The anasarca is well-documented but the treatment is missing from the chart, so SSA cannot tell whether the edema is persisting despite prescribed treatment or because no treatment was prescribed.

Every one of these gaps is fixable before the hearing. A return visit to the nephrologist with a request for explicit documentation of generalized edema, current diuretic regimen, and a repeat 24-hour collection or spot protein-to-creatinine ratio at the right interval can transform a denial-ready file into a 6.06 winner.

How a clean 6.06 file gets built

The strongest 6.06 files share a structure. Once you understand what SSA needs in the package, you can build it backward from the listing.

1. Nephrology longitudinal record. A series of clinic notes across at least 12 months showing consistent diagnosis, treatment escalation, and ongoing disease activity. Episodic visits do not work. SSA wants a relationship, not a snapshot.
2. Lab flowsheet. A table or run chart from the EMR showing serial proteinuria, serum albumin, creatinine, and eGFR values across the relevant period. This makes the 90-day rule trivial to verify and gives the adjudicator a one-page summary of severity.
3. Imaging and biopsy. Renal ultrasound to rule out obstruction and assess kidney size. Renal biopsy with light microscopy, immunofluorescence, and electron microscopy reports. If the biopsy predates the claim, include it anyway because it establishes the underlying pathology.
4. Specialty notes for complications. If there are thromboembolic events, hematology notes. If there is severe hyperlipidemia, lipid panel results. If there is recurrent infection, infectious disease consults. Each complication strengthens the picture of a serious, sustained illness.
5. Treating physician statement. A signed and dated statement from the treating nephrologist describing the syndrome, the response to treatment, the prognosis, and the functional limitations. This document should explicitly use the 6.06 language: lab findings on two occasions at least 90 days apart, anasarca persisting at least 90 days despite prescribed treatment.

If your file has all five elements, the listing case is straightforward. If it is missing any one of them, the case is at risk.

What if you do not meet 6.06 but still have severe disease?

Nephrotic syndrome that does not meet 6.06 can still win at SSA through three other paths.

Listing 6.03 chronic kidney disease with hemodialysis

If your nephrotic syndrome has progressed to end-stage renal disease requiring chronic hemodialysis or peritoneal dialysis, you meet Listing 6.03 automatically. This is true regardless of GFR or proteinuria.

Listing 6.04 chronic kidney disease with kidney transplantation

If you have had a kidney transplant, you are deemed disabled for one year following the transplant under Listing 6.04. After one year, SSA evaluates your residual function under 6.05 and the immunosuppression-related limitations under the relevant body system listings.

Listing 6.05 chronic kidney disease impairing function

If your nephrotic syndrome has reduced renal function to a serious level, 6.05 may apply. The criteria require eGFR of 20 mL/min/1.73 m squared or less on two occasions at least 90 days apart, or specific combinations of serum creatinine elevations with renal osteodystrophy, peripheral neuropathy, or fluid overload.

Medical equivalence under 20 CFR 404.1526

Even without meeting any specific listing, a claimant with severe nephrotic syndrome can satisfy the medical equivalence path. The argument requires a treating nephrologist statement that the combined functional impact equals listing-level severity. ALJs are receptive to this argument when the file shows persistent proteinuria, declining renal function, recurrent hospitalizations for volume overload, and aggressive immunosuppressive treatment.

RFC considerations

If your case does not clear Step 3, RFC is decided by the combined impact of nephrotic syndrome on physical and cognitive function. The factors that matter most:

• Fatigue from chronic hypoalbuminemia and edema. Patients with serum albumin in the low 2s typically have severe fatigue limiting standing and walking to 2 to 4 hours in an 8-hour day.
• Dietary and fluid restrictions. A claimant on a 2 gram sodium and 1.5 liter fluid restriction has medical needs that conflict with most work environments.
• Frequent medical appointments. Nephrology visits, labs, and possibly infusion therapy translate to documented absences.
• Immunosuppression-related restrictions. Steroids, cyclophosphamide, rituximab, calcineurin inhibitors all carry side effect profiles that limit work tolerance: weight gain, infection risk, neurocognitive effects, peripheral neuropathy.
• Risk of thromboembolism. Nephrotic patients have a markedly elevated risk of deep vein thrombosis and pulmonary embolism, which limits prolonged sitting or standing in some cases.

The combined RFC for a typical nephrotic syndrome claimant lands around sedentary work with frequent breaks, restricted to no more than 4 hours of standing or walking, with documented absences of 2 to 3 days per month for medical appointments and flares. That RFC often eliminates competitive employment under SSR 96-9p and SSR 24-3p VE testimony rules.

The five-step worked example

How to apply this listing to your case

1. Pull every 24-hour urine collection or spot urine protein-to-creatinine ratio in your nephrology file. Identify two qualifying values separated by at least 90 days within a 12-month window.
2. Pull every serum albumin in the file. Identify the matching low values.
3. Check the nephrology notes for explicit language describing generalized severe edema. If the language is weak, request a return visit and ask the nephrologist to document anasarca specifically.
4. Document the diuretic regimen, immunosuppressive regimen, and dietary restrictions.
5. Get a biopsy report if one exists.
6. If 6.06 does not fit, evaluate 6.03 (dialysis), 6.04 (transplant), 6.05 (impaired renal function), or medical equivalence.

Bottom line

Listing 6.06 is two criteria with a 90-day durability test on each. It is mechanical when the file is complete and impossible when the file has gaps. The fix is documentation. A 30-minute conversation with your nephrologist about what the chart needs to show usually closes the gap before a single denial.

If you have nephrotic syndrome and you are unsure whether your file meets 6.06, See If You Qualify and we will audit the lab record, the anasarca documentation, and the treatment chart against the listing before submission.

Related reading

• Listings 6.03, 6.04, 6.05 chronic kidney disease
• Disability benefits for lupus (lupus nephritis)
• Disability benefits for diabetes (diabetic nephropathy)
• Medical equivalence under 20 CFR 404.1526
• The five-step sequential evaluation

Frequently asked questions